Epirubicin
About
Therapy type: Chemotherapy
Therapy strategy: Topoisomerase inhibition
Mappings
NCI Thesaurus: Epirubicin (ncit:C62028)
RxNorm: epirubicin (rxcui:3995, omop:1344354)
SNOMED: Epirubicin (sctid:417916005, omop:4166710)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (4) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| EMA (1) FDA (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab | |
| EMA (2) FDA (2) HSE (1) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab | |
| EMA (2) FDA (2) HSE (1) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab |